

Comparison of the effect of Erythropoietin, L-Carnitine and Erythropoietin plus L-Carnitine in correction of anemia in chronic haemodialysis patients

| | | |
|--------------------------|---------------------------------|--|
| Submission date | Recruitment status | <input type="checkbox"/> Prospectively registered |
| 07/08/2005 | No longer recruiting | <input type="checkbox"/> Protocol |
| Registration date | Overall study status | <input type="checkbox"/> Statistical analysis plan |
| 11/08/2005 | Completed | <input type="checkbox"/> Results |
| Last Edited | Condition category | <input type="checkbox"/> Individual participant data |
| 25/09/2009 | Urological and Genital Diseases | <input type="checkbox"/> Record updated in last year |

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Hamid Tayebi Khosroshahi

Contact details

Dialysis Center
Imam Hospital
Daneshgah Street
Tabriz
Iran
+98 411 3344339
drtayebikh@yahoo.com

Additional identifiers

Protocol serial number

N/A

Study information

Scientific Title**Acronym**

Carnitine-Epo

Study objectives

Anemia in chronic haemodialysis patients is improved by administration of Erythropoietin or L-Carnitine or Erythropoietin plus L-Carnitine.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Chronic Renal Failure (End-Stage Renal Disease [ESRD])

Interventions

1. Administration of rHu-EPO 4000 IU/week, subcutaneously (SC) (2000 IU, twice weekly) for 3 months (N = 20)
2. Administration of L-Carnitine 500 mg/day, orally, for 3 months (N = 15)
3. Administration of rHu-EPO 4000 IU/week, SC PLUS L-Carnitine 500 mg/day, orally, for 3 months (N = 15)

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Erythropoietin, L-Carnitine

Primary outcome(s)

Haemoglobin level

Key secondary outcome(s)

Not provided at time of registration

Completion date

01/03/2005

Eligibility

Key inclusion criteria

1. Dialysis for more than 6 months
2. Hb less than 11 g/dl

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Active infectious disease
2. Active bleeding disorders

Date of first enrolment

01/03/2003

Date of final enrolment

01/03/2005

Locations

Countries of recruitment

Iran

Study participating centre

Dialysis Center

Tabriz

Iran

Sponsor information

Organisation

Tabriz University of Medical Sciences (Iran)

ROR

<https://ror.org/04krpx645>

Funder(s)

Funder type

University/education

Funder Name

Tabriz University of Medical Sciences (Iran)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration